Abstract Introduction This ecological study investigates the association between smoking prevalence and COVID-19 occurrence and mortality in 38 European nations as of 30th May 2020. Methods Data were collected from Our World in Data. Regression analysis was conducted to adjust for potential confounding factors such as economic activity (GDP), the rate of COVID-19 testing, and the stringency of COVID-19 control policies. Results There was a statistically significant negative association between smoking prevalence and the prevalence of COVID-19 across the 38 European nations after controlling for confounding factors (p = 0.001). A strong association was found between the prevalence of COVID-19 per million people and economic activity (p = 0.002) and the rate of COVID-19 testing (p = 0.0006). Nations with stricter policy enactment showed fewer COVID-19 cases per million people, but the association was not significant (p = 0.122). Delaying policy enactment was associated with a greater prevalence of COVID-19 (p = 0.0535). Evidence of a direct association between smoking prevalence and COVID-19 mortality was not found (p = 0.626). There was a strong positive association between COVID-19 mortality rate and the prevalence of COVID-19 cases (p < 0.0001) as well as the proportion of the population over 65 years of age (p = 0.0034) and a negative association with the rate of COVID-19 testing (p = 0.0023). Conclusions We found a negative association between smoking prevalence and COVID-19 occurrence at the population level in 38 European countries. This association may not imply a true or causal relationship, and smoking is not advocated as a prevention or treatment of COVID-19.

The SARS-CoV-2 virus, which causes Covid-19, induced a global pandemic for which an effective cure, either in the form of a drug or vaccine, has yet to be discovered. In the few brief months that the world has known Covid-19, there has been an unprecedented volume of papers published related to this disease, either in a bid to find solutions, or to discuss applied or related aspects. Data from Clarivate Analytics' Web of Science, and Elsevier's Scopus, which do not index preprints, were assessed. Our estimates indicate that 23,634 unique documents, 9960 of which were in common to both databases, were published between January 1 and June 30, 2020. Publications include research articles, letters, editorials, notes and reviews. As one example, amongst the 21,542 documents in Scopus, 47.6% were research articles, 22.4% were letters, and the rest were reviews, editorials, notes and other. Based on both databases, the top three countries, ranked by volume of published papers, are the USA, China, and Italy while BMJ, Journal of Medical Virology and The Lancet published the largest number of Covid-19-related papers. This paper provides one snapshot of how the publishing landscape has evolved in the first six months of 2020 in response to this pandemic and discusses the risks associated with the speed of publications.

No abstract

No abstract

There are currently eight vaccines against SARS-CoV-2 that have received Emergency Use Authorization by the WHO that can offer some protection to the world’s population during the COVID-19 pandemic. Though research is being published all over the world, public health officials, policymakers and governments are collecting evidence-based information to establish the public health policies. Unfortunately, continued international travel, violations of lockdowns and social distancing, the lack of mask use, the emergence of mutant strains of the virus and lower adherence by a sector of the global population that remains sceptical of the protection offered by vaccines, or about any risks associated with vaccines, hamper these efforts. Here we examine the literature on the efficacy, effectiveness and safety of COVID-19 vaccines, with an emphasis on select categories of individuals and against new SARS-CoV-2 strains. The literature shows that these eight vaccines are highly effective in protecting the population from severe disease and death, but there are some issues concerning safety and adverse effects. Further, booster shots and variant-specific vaccines would also be required.